Detalles de la búsqueda
1.
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry.
J Am Acad Dermatol;
2024 Apr 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38653344
2.
Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry.
Br J Dermatol;
189(3): 327-335, 2023 08 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-37177895
3.
Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry.
Acta Derm Venereol;
103: adv00872, 2023 Feb 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36794894
4.
Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis.
Allergy;
77(11): 3398-3407, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35837880
5.
Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry.
Acta Derm Venereol;
102: adv00820, 2022 Nov 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-36420885
6.
Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.
J Am Acad Dermatol;
84(4): 1000-1009, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32946967
7.
Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry.
Acta Derm Venereol;
101(10): adv00573, 2021 Oct 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-34396421
8.
Muscle and joint pain during dupilumab treatment for atopic dermatitis: Lack of association with antinuclear antibodies.
Clin Exp Allergy;
53(5): 582-585, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36779570
9.
Dupilumab has a profound effect on specific-IgE levels of several food allergens in atopic dermatitis patients.
Allergy;
78(3): 875-878, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36420598
10.
Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry.
Allergy;
75(9): 2376-2379, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32302412
11.
Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis.
JAMA Dermatol;
159(11): 1240-1247, 2023 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37851456
12.
Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis: A Prospective Clinical Cohort Study From the BioDay Registry.
JAMA Dermatol;
158(12): 1409-1413, 2022 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36322072
13.
Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab - a cross-sectional study from the BioDay registry.
J Dermatolog Treat;
33(4): 1986-1989, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-34151695
14.
Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry.
JAMA Dermatol;
158(9): 1048-1056, 2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35947364
15.
The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis.
Clin Transl Allergy;
13(1): e12219, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36705510
Resultados
1 -
15
de 15
1
Próxima >
>>